March 02, 2007
The United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers microRNAs (miRNAs) and therapeutic molecules that target these miRNAs.
The USPTO issued a “Notice of Allowance” for a patent application, which is derived from the “Tuschl III” patent series licensed co-exclusively to Alnylam and Isis for miRNA therapeutics on a worldwide basis through an agreement with Max Planck Innovation GmbH, the licensing agent for the Max Planck Society. The final issuance of the patent may be expected within six months.
Tuschl III patent series pertains to the discovery of over 120 mammalian miRNAs and stems from research performed by Alnylam founder Thomas Tuschl, Associate Professor of RNA Molecular Biology at The Rockefeller University, while at the Max Planck Society.
|
